Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated scores highest on Earnings (89) and lowest on Price (6). Its PosiPenta is 65.99 out of 100, better than most similar companies.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Details
PPrice
| P/E ratio | 238.89 |
| P/B ratio | 16.46 |
EEarnings
| Trailing EPS | ₹42.48 |
| Forward EPS | ₹415.79 |
NNitro
| Price | 10147.01 |
| 52-week high | 11929.11 |
| 52-week low | 2705.24 |
| Fall from 52-week high | 14.9% |
TTorque
| Return on equity (ROE) | 8.23% |
| Debt-to-equity | 0.01 |
AAnchor
| Beta (price swings) | 0.40 |
| Market cap | ₹1,09,687 Cr |
| Insider holding | 11.46% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Corcept Therapeutics Incorporated's PosiPenta score?
Corcept Therapeutics Incorporated's PosiPenta is 65.99 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Which PosiPenta pillar is strongest for Corcept Therapeutics Incorporated?
Earnings (growth), with a score of 89 out of 100: much better than most similar companies.
Which PosiPenta pillar is weakest for Corcept Therapeutics Incorporated?
Price (valuation), with a score of 6 out of 100: much weaker than most similar companies.
Has Corcept Therapeutics Incorporated's PosiPenta changed since last week?
Yes, it fell 0.95 points, from 66.94 to 65.99.
PositoAI is for research and education only and is not investment advice.